Sanofi Price to Sales Ratio 2010-2025 | SNY
Historical PS ratio values for Sanofi (SNY) over the last 10 years. The current P/S ratio for Sanofi as of May 23, 2025 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Sanofi P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2025-05-23 |
51.98 |
|
2.76 |
| 2025-03-31 |
53.11 |
$18.84 |
2.82 |
| 2024-12-31 |
46.18 |
$19.14 |
2.41 |
| 2024-09-30 |
55.18 |
$21.17 |
2.61 |
| 2024-06-30 |
46.46 |
$20.48 |
2.27 |
| 2024-03-31 |
44.65 |
$20.23 |
2.21 |
| 2023-12-31 |
45.68 |
$20.07 |
2.28 |
| 2023-09-30 |
49.28 |
$19.56 |
2.52 |
| 2023-06-30 |
49.51 |
$19.33 |
2.56 |
| 2023-03-31 |
48.11 |
$19.24 |
2.50 |
| 2022-12-31 |
42.81 |
$19.09 |
2.24 |
| 2022-09-30 |
33.61 |
$19.45 |
1.73 |
| 2022-06-30 |
44.23 |
$14.17 |
3.12 |
| 2022-03-31 |
43.67 |
$13.89 |
3.14 |
| 2021-09-30 |
41.00 |
$13.98 |
2.93 |
| 2021-06-30 |
44.79 |
$12.99 |
3.45 |
| 2021-03-31 |
40.54 |
$17.40 |
2.33 |
| 2020-09-30 |
41.12 |
$17.07 |
2.41 |
| 2020-03-31 |
34.55 |
$16.47 |
2.10 |
| 2019-09-30 |
36.61 |
$16.54 |
2.21 |
| 2019-03-31 |
33.59 |
$16.54 |
2.03 |
| 2018-03-31 |
28.94 |
$16.48 |
1.76 |
| 2017-12-31 |
31.05 |
$16.23 |
1.91 |
| 2017-09-30 |
35.95 |
$15.88 |
2.26 |
| 2017-06-30 |
34.59 |
$15.51 |
2.23 |
| 2017-03-31 |
31.64 |
$15.25 |
2.07 |
| 2016-12-31 |
28.27 |
$14.89 |
1.90 |
| 2016-09-30 |
26.70 |
$15.19 |
1.76 |
| 2016-06-30 |
29.26 |
$15.17 |
1.93 |
| 2016-03-31 |
26.94 |
$15.77 |
1.71 |
| 2015-09-30 |
31.85 |
$16.30 |
1.95 |
| 2015-06-30 |
33.23 |
$16.63 |
2.00 |
| 2014-06-30 |
34.52 |
$16.88 |
2.05 |
| 2013-06-30 |
32.27 |
$17.03 |
1.89 |
| 2012-06-30 |
22.88 |
$17.62 |
1.30 |
| 2012-03-31 |
22.37 |
$17.83 |
1.25 |
| 2011-12-31 |
21.10 |
$17.94 |
1.18 |
| 2011-09-30 |
18.94 |
$17.40 |
1.09 |
| 2011-06-30 |
23.19 |
$17.02 |
1.36 |
| 2011-03-31 |
19.40 |
$16.45 |
1.18 |
| 2010-12-31 |
17.75 |
$15.82 |
1.12 |
| 2010-09-30 |
18.31 |
$15.82 |
1.16 |
| 2010-06-30 |
16.56 |
$15.87 |
1.04 |
| 2010-03-31 |
19.51 |
$15.83 |
1.23 |
| 2009-12-31 |
20.51 |
$15.62 |
1.31 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$132.654B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
